Skip to main content

Table 1 Study characteristics of the 22 included studies

From: Acquisition of multidrug-resistant Enterobacterales during international travel: a systematic review of clinical and microbiological characteristics and meta-analyses of risk factors

Study

Year

Country

Study period

Population characteristic

Study sizea

Proportion of MDR E. colie in post-travel isolates

Sample time (range) before/after travel

Median duration of travel in days (range)

Follow-up of carriage

Kennedy [21]

2010

Australia

January 2008–April 2009

Hospital staff and contacts

102

> 92% E. colib

Within 2 weeks before and after

21 (9–135)

6 months

Tängdén [12]

2010

Sweden

November 2007–January 2009

Travel clinic

100

100% E. coli (24/24b)

Unknown

14 (7–182)

6 months

Weisenberg [22]

2012

United States

July 2009–February 2010

Travel clinic

28

E. coli 100% (7/7b)

1 week before/within 1 week after

14 (8–42)

None

Östholm-Balkhed* [23, 24]

2013

Sweden

September 2008–April 2009

Vaccination clinic

231

90% E. coli (104/116)b

15 (1–114) days/ 3 (0–191) days

16 (4–119)

12 months

Paltansing* [25]

2013

The Netherlands

March 2011–September 2011

Travel clinic

370

92% E. coli (146/158)c

Immediately before and after

21 (6–90)

6 months

Kuenzli* [26]

2014

Switzerland

December 2012–October 2013

Travel clinic

190

98% E. coli (157/161b)

Week before/directly after

Mean; 18 (5–35)

None

von Wintersdorff [27]

2014

The Netherlands

November 2010–August 2012

Travel clinic

122

ND

Before and immediately after

21 (5–240)

None

Angelin* [28]

2015

Sweden

April 2010–January 2014

Healthcare students

99

100% E. coli (35/35c)

Close to departure/ 1–2 weeks after return

45 (13–365)

None

Kantele* [29]

2015

Finland

March 2009–February 2010

Travel clinic

430

97% E. coli (94/97b)

Before/first (or second) stool after

Mean; 19 (4–133)

12 months

Lübbert [30]

2015

Germany

May 2013–April 2014

Travel clinic

205

92% E. coli (58/63b)

Before/within 1 week after

21 (2–218)

6 months

Ruppé* [31]

2015

France

February 2012–April 2013

Vaccination centers

574

93% E. coli (491/526b)

Within 1 week before and after

20 (IQR 15–30)

12 months

Bernasconi [32]

2016

Switzerland

January 2015–August 2015

Unknown

38

90% E. coli (26/29b)

Within 1 week before and after

Mean; 15 (8–35)

6 months

Mizuno [33]

2016

Japan

September 2012–March 2015

Business travelers

57

ND

Before and at time of return

> 6 months

None

Reuland* [34]

2016

The Netherlands

April 2012–April 2013

Vaccination clinic

445

97% E. coli (95/98b)

Before/within 2 weeks after

Mean; 14 (1–105)

None

Vading* [35]

2016

Sweden

April 2013–May 2015

Travel clinic

188

97% E. coli (65/67b)

Unknown

14 (IQR 8–20)

10 to 26 months

van Hattemd [36]

2016

The Netherlands

November 2012–November 2013

Travel clinic

2001

60% E. coli (3/5b)

Before/immediately and 1 month after travel

20 (IQR 15–25)

12 months

Arcilla*d [37]

2017

The Netherlands

November 2012–November 2013

Travel clinic

2001

88% E. coli (759/859b)

Before/immediately and 1 month after travel

20 (IQR 15–25)

12 months

Leangapichart* [38]

2017

France

Hajj 2013 & 2014

Hajj pilgrims

218

ND

Just before departure and after the Hajj just before return

22 and 24

None

Peirano* [39]

2017

Canada

January 2012–July 2014

Travel clinic

116

100% E. coli (124/124b)

Before /within 1 week after

10–38

6 months

Bevan [40]

2018

United Kingdom

March 2015–June 2016

University and university hospital

18

100% E. coli (16/16)

As close to the time of sample submission and after

21, mean 27

Up to 12 months

Nakayama [41]

2018

Japan

June 2015–August 2016

Unknown

19

100% E. coli

Before and up to 2 weeks after

2–12 days

None

Schaumburg* [42]

2019

Germany/the Netherlands

October 2016–March 2018

Vaccination center

132

ESBL-producing Enterobacterales

Up to 1 week before departure, during travel and up to 1 week after return

Mean: 18.7, maximum of six weeks

6 months (137–420 days after return)

  1. Abbreviations: E. coli, Escherichia coli; MDR Multidrug-resistant; ND No data; *, included in the meta-analyses
  2. a Number of travelers who provided pre-travel and post-travel samples
  3. b MDR microorganisms newly acquired during travel
  4. c Data about post-travel samples
  5. d Reported on the same study population, however, van Hattem et al. reported on CPE acquisition, and Arcilla et al. on ESBL-E acquisition
  6. e Including ESBL-producing E. coli and carbapenemase-producing E. coli